Low-Dose Radiation Therapy for Osteoarthritis: Analysis of Preliminary Outcomes at Scripps Clinic Authors: Olumide A. Ojo, Abigail Lin, Norbert Kased, Shane Mesko, Eric Hu, Samantha Bagsic, Thomas A. Buchholz, Chien Peter Chen, Prabhakar Tripuraneni, Anuradha Koka, Patrick Linson, Ken Shimizu, Eva Lean, Ray Lin Published: 2026 ABSTRACT PurposeOsteoarthritis (OA) is a chronic, degenerative joint disease affecting approximately 15% of Americans, resulting in significant pain, functional impairment, and diminished quality of life (QoL). Many patients have symptoms refractory to conventional treatments including lifestyle modification, topical and oral analgesics as well as intra-articular therapy. Low-dose radiation therapy (LDRT) has been used for many decades in Europe to manage OA symptoms, but this treatment remains underutilized in the United States. Since June 2024, LDRT has been routinely used in our clinic to treat OA. This study evaluates early clinical outcomes.Methods and MaterialsWe retrospectively reviewed patients aged 46 to 96 who received LDRT for OA between June 1, 2024, and May 31, 2025. During this period, departmental policy limited treatment to nonpregnant adults and peripheral joints. Demographics, joint site, imaging, prior therapies, radiation dose, and treatment dates were extracted from the medical record. All patients received 3 Gy in 0.5-Gy fractions over ∼10 days. Standardized forms were completed at baseline and at 2-, 6-, and 12-month follow-up, assessing pain (Visual Analog Scale), analgesic use (days/week), and activities of daily living/QoL impact (1-10 scale). Range of motion and treatment-related side effects were also documented.ResultsA total of 167 patients and 184 joints were treated with LDRT for OA. Patients with no follow-up were excluded from the study. Patients had statistically significant improvement in pain scores, reduced analgesic use, and enhanced QoL. Among 184 joints, 88% noted a decrease in pain following treatment at the first follow-up visit. The mean pain scores decreased from 6.31 ± 2.07 pretreatment to 2.51 ± 2.80 at follow-up (paired t test P < .01; Wilcoxon P < .01). In addition, analgesic use (−0.92 d/wk ± 2.00; P < .01), QoL (−2.13 ± 2.20; P < .01), and impact on activities of daily living (−2.05 ± 2.30; P < .01) all showed significant improvements based on mean score reductions. There was no grade 2 or greater treatment-related toxicities.ConclusionsLDRT is an effective noninvasive treatment for OA with minimal adverse effects. These findings support further study and broader consideration of clinical use in the United States. Introduction Osteoarthritis (OA) is a degenerative joint disease and the most widespread musculoskeletal condition in the United States (US), affecting an estimated 32.5 million adults, nearly 15% of the population.1,2 The burden of OA is expected to rise with the aging US population and increasing prevalence of obesity, a well-established risk factor for both the incidence and progression of OA.3 Demographically, OA is disproportionately represented in women, older adults, and individuals with a history of joint trauma or physically demanding occupations. OA is among the most costly medical conditions in the US, accounting for approximately 65 billion dollars in direct medical cost annually.1 OA is also a leading cause of chronic pain, functional limitation, and diminished quality of life (QoL). Nearly 1 million hip and knee replacement surgeries are undertaken each year and contribute to substantial health care utilization.3 Conservative management of OA typically involves initial lifestyle modification (weight loss and physical activity), physical therapy, topical and oral analgesics, with intra-articular therapy (corticosteroid or hyaluronic acid injections) used for persistent symptoms.4 However, these therapies often provide only limited and short-term relief, with effectiveness further reduced in older adults with comorbidities.1 For patients with refractory symptoms, joint replacement surgery may be considered. However, this intervention is invasive, costly, and precluded by age/comorbidities or is declined by patients.2 Low-dose radiation therapy (LDRT) has been used in Europe for OA and other benign musculoskeletal disorders, with observational studies reporting 40% to 90% of patients experiencing pain relief and functional improvement.5,6 The biological rationale for LDRT lies in its systemic anti-inflammatory effects. Preclinical studies demonstrate that LDRT suppresses proinflammatory cytokines (tumor necrosis factor alpha, interleukin [IL]-1 beta, and IL-6), reduces leukocyte endothelial interactions, and induces apoptosis in activated inflammatory cells.7 LDRT also increases regulatory CD4 positive T cells relative to proinflammatory CD8 positive cells, enhances anti-inflammatory mediators such as transforming growth factor beta 1 and osteoprotegerin, and modulates osteoprotegerin Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) signaling to inhibit osteoclast formation and bone resorption.5,7 Furthermore, Deloch et al8 showed cellular effects on osteoblast/osteoclast regulation and cytokine release under LDRT, which also repolarizes immune cell phenotypes by enhancing CD4 regulatory T-cell subsets over CD8 effector cells to create an anti-inflammatory microenvironment within treated joints. Additional findings suggest mitochondrial modulation and mitohormetic signaling, including increased GDF15, contribute to its chondroprotective and analgesic effects.9 Collectively, these mechanisms provide a strong biological basis for the observed clinical benefits. Despite its established safety and widespread use in Europe, LDRT remains underused in the US because of concerns about radiation-induced malignancy and limited randomized evidence.1,3 This study represents the largest modern American case series assessing LDRT’s effectiveness and safety in OA. Methods and Materials Study design and ethical considerations The retrospective study was conducted within our clinic. We reviewed records of all the patients treated with LDRT for OA between June 1, 2024, and May 31, 2025. The study protocol was approved by the institutional review board. In accordance with institutional guidelines, the institutional review board waived the requirement to obtain informed consent. All data were anonymized before analysis, and those data were kept confidential per stringent institutional protocol. Patient characteristics Demographic and clinical data were retrieved, including age, sex (male or female), comorbidities (eg, obesity, diabetes mellitus, and cardiovascular disease), joint location, and previous therapies. Prior conservative interventions, which included physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and intra-articular injections, were documented. Treated joints were stratified into 6 anatomic categories: foot/ankle, knee, hip, shoulder, elbow, and hand/wrist. In subsets of patients treated on a multijoint basis, individual joint analysis was done based on the outcomes. Treatment protocol LDRT was administered using a Varian Clinac iX linear accelerator and Varian True Beams (Varian Medical Systems). Treatment planning employed a 2-dimensional or 3-dimensional conformal technique, primarily using anterior-posterior/posterior-anterior parallel opposed fields for large joints (knee, hip, ankle/foot, shoulder, and elbow). Single posterior fields were used for the hand and thumb with a 5 to 10 mm bolus. Patient positioning and immobilization were customized for each patient and joint. Treatment was delivered using 6 to 15 MV photons depending on patient thickness. Guidelines from recent reviews and the German Society for Radiation Oncology were used for field design.22 Each course of treatment consisted of 0.5 Gy per fraction, for a total of 6 fractions (3 Gy total) over approximately 10 to 14 days. A second course of treatment was administered at least 6 to 12 weeks after the initial course in select patients with inadequate response to the initial course of treatment (at the physician’s discretion and per patient preference). Outcome measures An in-house developed questionnaire was given to patients to complete before treatment and following their radiation therapy (Fig. 1).Figure 1In-house developed questionnaire.Figure 1 dummy alt text In-house developed questionnaire. The following outcome metrics were recorded:•Pain severity assessed using the Visual Analog Scale (VAS, 0-10).•Analgesic use, measured in days per week.•Impact on QoL and activities of daily living (ADLs) (self-reported on a scale of 0-10 with higher scores indicating a greater adverse impact).•Document treatment-related adverse events, including fatigue, erythema, skin, or nail changes. •Pain severity assessed using the Visual Analog Scale (VAS, 0-10). Pain severity assessed using the Visual Analog Scale (VAS, 0-10). •Analgesic use, measured in days per week. Analgesic use, measured in days per week. •Impact on QoL and activities of daily living (ADLs) (self-reported on a scale of 0-10 with higher scores indicating a greater adverse impact). Impact on QoL and activities of daily living (ADLs) (self-reported on a scale of 0-10 with higher scores indicating a greater adverse impact). •Document treatment-related adverse events, including fatigue, erythema, skin, or nail changes. Document treatment-related adverse events, including fatigue, erythema, skin, or nail changes. Assessment timeline Measurements were taken at baseline (pretreatment), end of treatment, and follow-up time points up to 12 months after treatment. Although follow-up visits were generally scheduled at 2, 6, and 12 months, primary outcome analysis was based on the first available follow-up visit. Follow-up and data completeness Data were primarily collected in person during clinic and telemedicine visits. Some patients who did not return for scheduled follow-up provided only baseline and end-of-treatment data. This introduced the potential for a selection bias because patients with greater improvement of symptoms may have been less likely to return for long-term evaluation. To establish this, sensitivity analyses were carried out to examine the robustness of the treatment effect within the subgroup of patients who had complete follow-up. For outcome analysis, only data from the first follow-up visit were used to minimize bias associated with variable follow-up duration. Statistical analysis All data processing and basic statistical analyses were conducted in a Python 3.7.3 environment using Jupyter Notebook (Anaconda version 23.1.0) with the pandas, NumPy, and SciPy libraries. Continuous data (eg, pain ratings and QoL ratings) were expressed as means with SD, whereas categorical data (eg, sex, comorbidities, and joint affected) were expressed in frequency and percentage.•Pain outcomes: paired t-tests compared baseline and follow-up VAS scores; the results were evaluated with Wilcoxon signed-rank tests.•Analgesic use and QoL scores: within-subject comparisons across time points were evaluated using paired comparisons.•Joint-specific analyses: one-way analysis of variance examined differences in treatment effect between anatomic joint groups. •Pain outcomes: paired t-tests compared baseline and follow-up VAS scores; the results were evaluated with Wilcoxon signed-rank tests. Pain outcomes: paired t-tests compared baseline and follow-up VAS scores; the results were evaluated with Wilcoxon signed-rank tests. •Analgesic use and QoL scores: within-subject comparisons across time points were evaluated using paired comparisons. Analgesic use and QoL scores: within-subject comparisons across time points were evaluated using paired comparisons. •Joint-specific analyses: one-way analysis of variance examined differences in treatment effect between anatomic joint groups. Joint-specific analyses: one-way analysis of variance examined differences in treatment effect between anatomic joint groups. Results Patient demographics Patient demographics are delineated in Table 1. Between June 2024 and May 2025, 184 joints (167 patients) were treated with LDRT for OA. Nearly all patients had tried some form of conservative treatment, including lifestyle modification, physical therapy, topical and oral analgesics, or intra-articular therapy (corticosteroid or hyaluronic acid injections) prior to their LDRT.Table 1Participant demographics (N = 167)Table 1 dummy alt textVariablen (%)Mean ± SDMedianAge (y)Range (46-96)75.7 ± 9.376BMI (kg/m²)28.2 ± 6.327.5Sex Female85 (50.9)-- Male82 (49.1)--Race White144 (86.2)-- Asian13 (7.8)-- Black or African American3 (1.8)-- Other5 (3.0)--Ethnicity Hispanic/Latino10 (6.0)-- Not Hispanic/Latino152 (91.0)--Status Alive160 (97.0)-- Deceased5 (3.0)--Smoking Never91 (55.2)-- Former65 (39.4)-- Current6 (3.6)--Language English160 (95.8)--Marital status Married104 (63.0)-- Widowed27 (16.4)-- Single15 (9.1)-- Divorced13 (7.9)-- Legally separated1 (0.6)-- Table 1Participant demographics (N = 167)Table 1 dummy alt textVariablen (%)Mean ± SDMedianAge (y)Range (46-96)75.7 ± 9.376BMI (kg/m²)28.2 ± 6.327.5Sex Female85 (50.9)-- Male82 (49.1)--Race White144 (86.2)-- Asian13 (7.8)-- Black or African American3 (1.8)-- Other5 (3.0)--Ethnicity Hispanic/Latino10 (6.0)-- Not Hispanic/Latino152 (91.0)--Status Alive160 (97.0)-- Deceased5 (3.0)--Smoking Never91 (55.2)-- Former65 (39.4)-- Current6 (3.6)--Language English160 (95.8)--Marital status Married104 (63.0)-- Widowed27 (16.4)-- Single15 (9.1)-- Divorced13 (7.9)-- Legally separated1 (0.6)-- Participant demographics (N = 167) The distribution of treated joints was 72 knees (39.1%), 41 hands (22.3%), 29 hips (15.8%), 23 shoulders (12.5%), 15 feet/ankles (8.2%), and 4 elbows (2.1%). Several patients were treated in several joints, and they were individually analyzed. A total of 145 patients completed at least 1 follow-up visit after treatment. Among these, 17 patients were seen for two 6-ups, 2 no follow-ups, and only 1 patient completed 3 follow-up visits. The mean time for follow-up was 68 days with an SD of 48.7 days. The median interval was 62 days (range, 2-434 days). These clinical benefits were accompanied by analgesic diminution and improved QoL/daily functioning. No significant adverse effects were reported. Few patients noted nail changes, but nails were blocked out of the treatment fields Pain outcomes Pretreatment to end of treatment At baseline, the mean VAS score across all joints was 6.31 ± 2.07. At the first follow-up visit (mean, 68 days; SD, 48.7; median, 62), the mean VAS score decreased to 2.51 ± 2.80 (paired t test, P < .01; Wilcoxon, P < .01). These data are displayed in Figure 2 and stratified by joint in Table 2. As shown in Table 2, 88% of patients reported a decrease in pain scores at the first follow-up, and all joint sites demonstrated improvement in at least 80% of patients. Of note, because only the data from the first follow-up examination are representative, only these were evaluated and reported (possible bias when integrating response rates from later follow-up examinations).Figure 2Mean pain scores before therapy (red) and at follow-up (blue) across 6 joint categories. Joint score comparisons (before vs follow-up, all joints).Figure 2 dummy alt textTable 2Pain score changes by joint (N = 184) pretreatment versus follow-upTable 2 dummy alt textVariableIncreased scoreDecreased scoreNo change in scoreHand/wrist5/46 (10.9%)39/46 (84.8%)2/46 (4.3%)Shoulder1/24 (4.2%)20/24 (83.3%)3/24 (12.5%)Hip0/33 (0.0%)31/33 (93.9%)2/33 (6.1%)Knee2/70 (2.9%)63/70 (90.0%)5/70 (7.1%)Foot/ankle1/11 (9.1%)9/11 (81.8%)1/11 (9.1%)Combined9/184 (4.9%)162/184 (88.0%)13/184 (7.1%)Abbreviations: ADL = activities of daily living; QoL = quality of life.Combined table for analgesic use, QoL, and ADL. Mean pain scores before therapy (red) and at follow-up (blue) across 6 joint categories. Joint score comparisons (before vs follow-up, all joints). Table 2Pain score changes by joint (N = 184) pretreatment versus follow-upTable 2 dummy alt textVariableIncreased scoreDecreased scoreNo change in scoreHand/wrist5/46 (10.9%)39/46 (84.8%)2/46 (4.3%)Shoulder1/24 (4.2%)20/24 (83.3%)3/24 (12.5%)Hip0/33 (0.0%)31/33 (93.9%)2/33 (6.1%)Knee2/70 (2.9%)63/70 (90.0%)5/70 (7.1%)Foot/ankle1/11 (9.1%)9/11 (81.8%)1/11 (9.1%)Combined9/184 (4.9%)162/184 (88.0%)13/184 (7.1%)Abbreviations: ADL = activities of daily living; QoL = quality of life.Combined table for analgesic use, QoL, and ADL. Pain score changes by joint (N = 184) pretreatment versus follow-up Abbreviations: ADL = activities of daily living; QoL = quality of life. Combined table for analgesic use, QoL, and ADL. Table 2 demonstrates that 88% of patients experienced a reduction in pain scores between pre-RT and the end of follow-up. Analgesic use, QoL, and ADL scores all demonstrated statistically significant improvements following therapy, Table 3 shows that analgesic scores decreased by a mean of −0.92 (SD, 2.00; P < .01, paired t test; P < .01, Wilcoxon). QoL improved with a mean change of −2.13 (SD, 2.20; paired t test, P < .01; Wilcoxon, P < .01). Similarly, ADL scores improved by a mean of −2.05 (SD, 2.30; P < .01, paired t test; P < .01, Wilcoxon).Table 3Analgesic use, quality of life (QoL), and activities of daily living (ADL) scores before and after therapyTable 3 dummy alt textVariableUnits/scalenBefore therapy (mean ± SD)At follow-up (mean ± SD)P value (paired t test)P value (Wilcoxon)Analgesic used/wk783.96 ± 2.653.04 ± 2.461.20 × 10-42.69 × 10-4Quality of life (QoL)0-10796.43 ± 2.644.30 ± 2.917.07 × 10-131.86 × 10-10Activities of daily living (ADL)0-10766.25 ± 2.594.20 ± 2.984.21 × 10-111.64 × 10-9Second course of treatment. Table 3Analgesic use, quality of life (QoL), and activities of daily living (ADL) scores before and after therapyTable 3 dummy alt textVariableUnits/scalenBefore therapy (mean ± SD)At follow-up (mean ± SD)P value (paired t test)P value (Wilcoxon)Analgesic used/wk783.96 ± 2.653.04 ± 2.461.20 × 10-42.69 × 10-4Quality of life (QoL)0-10796.43 ± 2.644.30 ± 2.917.07 × 10-131.86 × 10-10Activities of daily living (ADL)0-10766.25 ± 2.594.20 ± 2.984.21 × 10-111.64 × 10-9Second course of treatment. Analgesic use, quality of life (QoL), and activities of daily living (ADL) scores before and after therapy Second course of treatment. In total, 78 patients had complete analgesic use and QoL/ADL data. The discrepancy between the total number of treated joints and the number included in these analyses is primarily because of incomplete documentation. Specifically, not all patients had both pretreatment and posttreatment forms completed. In some cases, pain scores were recorded in the clinical chart, but analgesic use was not documented. Others had complete pretreatment forms but lacked posttreatment forms, with only posttreatment pain scores available from chart entries. Analgesic use decreased significantly, indicating a meaningful reduction in analgesic demand following LDRT. Second course of treatment A total of 29 patients (32 joints) underwent a second course of LDRT. As shown in Table 4, retreatment produced additional pain reduction across several joint groups. Overall, 71.9% of retreatment joints demonstrated a decrease in pain score, which is lower than the 88% response rate observed after the initial treatment course. Among joints that improved, the hand/wrist, knee, and combined analyses showed statistically significant reductions in pain (P < .01). Improvements in the shoulder, hip, and foot and ankle groups followed similar downward trends but did not reach statistical significance.Table 4Pain score changes following a second course of low-dose radiation therapy by joint siteTable 4 dummy alt textVariableBefore therapy, mean (SD)First course FU, mean (SD)Second course FU, mean (SD)P value (paired t test, 1st FU vs baseline)P value (Wilcoxon, 1st FU vs baseline)P value (paired t test, 2nd FU vs 1st FU)P value (Wilcoxon, 2nd FU vs 1st FU)Hand/wristn = 9; 5.78 (1.69)n = 9; 4.50 (1.91)n = 9; 1.78 (2.35).0685.0977.0281.0391Shouldern = 4; 6.50 (2.29)n = 4; 5.00 (1.58)n = 4; 3.25 (1.92).4058.4142.0689.1025Hipn = 3; 6.67 (1.89)n = 3; 1.00 (1.41)n = 3; 1.67 (1.70).1358.25.7418.6547Kneen = 13; 6.92 (2.09)n = 13; 4.54 (3.65)n = 13; 1.54 (2.02).0106.0183.014.0114Foot/anklen = 3; 7.67 (2.05)n = 3; 6.3 (2.62)n = 3; 3.33 (0.94).71571.0.1885.25Combinedn = 32; 6.59 (2.07)n = 32; 4.42 (3.01)n = 32; 2.00 (2.12).0004.0009.0002.0002Abbreviation: FU = follow-up. Table 4Pain score changes following a second course of low-dose radiation therapy by joint siteTable 4 dummy alt textVariableBefore therapy, mean (SD)First course FU, mean (SD)Second course FU, mean (SD)P value (paired t test, 1st FU vs baseline)P value (Wilcoxon, 1st FU vs baseline)P value (paired t test, 2nd FU vs 1st FU)P value (Wilcoxon, 2nd FU vs 1st FU)Hand/wristn = 9; 5.78 (1.69)n = 9; 4.50 (1.91)n = 9; 1.78 (2.35).0685.0977.0281.0391Shouldern = 4; 6.50 (2.29)n = 4; 5.00 (1.58)n = 4; 3.25 (1.92).4058.4142.0689.1025Hipn = 3; 6.67 (1.89)n = 3; 1.00 (1.41)n = 3; 1.67 (1.70).1358.25.7418.6547Kneen = 13; 6.92 (2.09)n = 13; 4.54 (3.65)n = 13; 1.54 (2.02).0106.0183.014.0114Foot/anklen = 3; 7.67 (2.05)n = 3; 6.3 (2.62)n = 3; 3.33 (0.94).71571.0.1885.25Combinedn = 32; 6.59 (2.07)n = 32; 4.42 (3.01)n = 32; 2.00 (2.12).0004.0009.0002.0002Abbreviation: FU = follow-up. Pain score changes following a second course of low-dose radiation therapy by joint site Abbreviation: FU = follow-up. Discussion This retrospective analysis of 167 patients and 184 joints represents the largest modern single-institution US cohort of patients with OA treated with LDRT. Pain scores decreased significantly from baseline through completion of treatment and maintained improvement on follow-up. These clinical benefits were accompanied by analgesic diminution and improved QoL/daily functioning. The VAS demonstrated the efficacy of LDRT, with 88% of joints showing pain reduction between pretreatment and follow-up. At baseline, patients reported moderate-to-severe pain across all treated joints. The knee and hand/wrist joints showed the most notable improvements, while the shoulder, hip, and foot/ankle groups exhibited similar downward trends that did not reach statistical significance, likely because of smaller sample sizes. Overall, the results indicate that a single course of LDRT provides meaningful and statistically significant pain relief, particularly in the knee and hand/wrist joints, supporting its efficacy as an initial noninvasive therapy for OA-related pain. Our findings closely correlate with European observational series consistently demonstrating clinically meaningful responses to LDRT. Hautmann et al10 reported sustained long-term improvement in 295 joints treated with linear accelerator–based LDRT, with scores for pain decreasing from 7 to 3 at 24 months, demonstrating similar sustained effectiveness to our observed decreases. A large multicenter series was reported by Rühle et al4, involving 970 patients and 1185 treated sites, of whom approximately two-thirds were elderly (median age, 76 years). The efficacy of LDRT was evaluated across different joint categories and age groups, demonstrating significant pain reduction after treatment and at follow-up (P < .001 for all timepoint comparisons). At follow-up, pain responses were observed in over 60% of reirradiated sites, with outcomes remaining consistent across age groups. These findings support the reproducible analgesic effect of LDRT and are consistent with the current study, which also demonstrated significant and sustained pain relief following one or more courses of therapy.4 In addition, preliminary results from the Low-dose Radiation therapy for patients with KNee osteoArthritis (LoRD-KNeA) trial, which is a multicenter, randomized, and sham-controlled study from Korea are already demonstrating symptomatic improvements in patients treated with LDRT versus patients who were treated with sham radiation at 4 months.11 Additionally, a double-blind, sham-controlled trial from Iran for knee OA is also showing functional improvements in patients receiving LDRT to the knee versus those patients who received sham radiation.12 Our study provides data showing patterns of benefit consistent with the extensive European observational experience, suggesting that selection criteria for patients, standardized protocol, and extended follow-up periods are likely significant determinants of closing perceived gaps between randomized and observational evidence. A total of 29 patients underwent a second course of LDRT. As shown in Table 4, these patients experienced additional and statistically significant pain reduction in the hand/wrist. The shoulder, hip, and foot/ankle joints showed similar numerical improvements but did not reach statistical significance, likely reflecting the smaller subgroup sizes. These results suggest that sequential courses of LDRT may produce additive and durable analgesic effects. Our findings provide new insight into the clinical utility of LDRT retreatment. Although repeat courses produced additional pain relief, the greatest improvements occurred in single-course responders, particularly in the knee and hand/wrist joints. These patterns align with large European observational studies, underscoring the importance of patient selection, standardized protocols, and long-term follow-up in optimizing therapeutic outcomes These outcomes concur with Hautmann’s series of 217 retreatment joints, where reirradiation yielded meaningful pain reduction but demonstrated diminishing returns relative to the initial course.13 This strategy maximizes therapeutic benefit while minimizing cumulative radiation exposure and overall health care utilization. Site-specific analyses have further supported these trends: Hautmann’s subsequent evaluation of 66 ankle and tarsal joints showed consistent improvement across subregions,14 and Álvarez et al15 documented substantial pain relief and functional recovery in patients with hand OA, mirroring the favorable results observed in our hand/wrist subgroup. Collectively, these data reinforce the clinical value of targeted LDRT while highlighting the potential for diminishing efficacy in repeated courses. From the clinical perspective, these findings highlight the high potential of LDRT as a cost effective, noninvasive, and well-tolerated treatment modality for OA in the US health care system. Within the context of rising prevalence of OA in conjunction with the aging population and obesity rates, as well as the ongoing opioid epidemic as a critical public health problem, the existence of an intervention that can significantly reduce pain, decrease the use of analgesic drugs, and increase the QoL with minimal adverse effects holds specific clinical significance. This can be an adjunct to surgical interventions, which are costly, invasive, and usually not feasible for most elderly patients with several comorbid diseases. Its availability as an outpatient modality with brief treatment duration and minimum interference with daily routines further adds to its clinical utility and patient acceptability. Importantly, reducing reliance on conventional analgesics such as NSAIDs can have significant downstream benefits by mitigating associated risks. NSAIDs are well known to increase the likelihood of serious gastrointestinal complications, including peptic ulcers, bleeding, and perforation, as well as cardiovascular events like myocardial infarction and heart failure, and renal impairment through nephrotoxicity and alterations in renal blood flow.16 These risks are particularly pronounced in vulnerable populations, such as the elderly or those with comorbidities, and even short-term use can precipitate adverse events. While translational and observational evidence strongly attest to the effectiveness of LDRT, randomized controlled trials have mixed findings, which need to be interpreted cautiously. Minten et al17 and Mahler et al18 found no difference between sham and LDRT in patients with hand and knee osteoarthritis, respectively. These trials have been extensively criticized for statistical design and methodology.19 However, other randomized trials and systematic reviews have shown substantial clinical gains, and methodological reviews note substantial heterogeneity in trial design, fractionation schedules, endpoints, and follow-up as important confounders to make direct comparison impossible. Donaubauer et al20 described substantial pain alleviation and Dove et al1 provided a comprehensive overview of the US experience and pointed toward the potential use of LDRT in the treatment of OA. Our study provides robust real-world US data showing patterns of benefit consistent with the extensive European observational experience, suggesting that selection criteria for patients, standardized protocol, and extended follow-up periods are likely significant determinants of closing perceived gaps between randomized and observational evidence. Koneru et al21 presented the first US LDRT retrospective analysis for OA, showing significant pain reductions (40.4→26.0; P < .05) sustained at follow-up. Eighty percent improved, 72% maintained benefit, and retreatment provided additional relief, supporting durable efficacy across joint types. Future research priorities should focus on prospective, randomized, controlled studies conducted in the US health care context to confirm these observational findings. Additionally, OA is a complex and multifaceted disease. There are many phenotypes in OA based on clinical characteristics and mechanisms that affect disease progression—genetics, metabolic, hormone-related, overuse/mechanical, weight-related, age-related, and injury-related. It is not uncommon for a patient to have multiple risk factors. Perhaps, identifying the phenotype can help determine and customize the best treatment. Biomarker-driven studies and long-term prospective follow-up are needed to clarify LDRT’s mechanisms, identify responders, assess durability, and define late safety. Economic analyses comparing LDRT with standard care will further inform its value in the US health care system. This study has several limitations, including its retrospective design, wide variation in follow-up duration (2-434 days), missing data with about 12.5% of joints lost to follow-up, and small subgroup sizes for foot and ankle and retreatment cases, which reduce statistical power. The study period was also too short to assess long-term safety, although extensive European experience indicates that the risk of malignancy at LDRT doses is extremely low. Our study adds to the growing literature showing that LDRT is an effective and safe treatment for symptom palliation in US patients with OA. This treatment was found to ameliorate pain, enhance functional outcomes, and reduce analgesic use with minimal treatment-related toxicity. These results add to the growing body of evidence demonstrating LDRT efficacy and promote the proposed development of prospective clinical research to clearly define the role of LDRT in contemporary evidence-based multidisciplinary treatment of OA. The favorable risk-benefit ratio and convenient therapy implementation characteristics make it a valuable therapeutic tool in the arsenal against this widespread and disabling disease. Conclusion LDRT resulted in significant improvement in pain and QoL in patients with OA with minimal adverse effects in the US. These findings suggest that LDRT should be considered a feasible adjunct to other available treatment options. Standardized prospective trials with long-term follow-up are necessary to replicate these findings. Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.